What is Disc Medicine's debt issuance proceeds?

Disc Medicine (IRON) reported debt issuance proceeds of $0 in Q4 2025.

How has Disc Medicine's debt issuance proceeds changed year-over-year?

Disc Medicine's debt issuance proceeds decreased by 100.0% year-over-year, from $7.25M to $0.

Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.

Beam TherapeuticsBEAM

$93.89M—

BridgeBio PharmaBBIO

——

Operating income-$69.5M-74.0%

Net income-$63.5M-86.3%

EPS (diluted)-$1.65-61.8%

Cash & equivalents$88.9M-27.5%

Total debt$31.1M+1.4%

Total equity$688.4M+4.3%

Total assets$750.2M+5.8%

Operating cash flow-$62.2M-50.4%

CapEx--100%

Free cash flow-$62.2M-47.4%

Market cap$2.69B+42.2%

Enterprise value$2.63B+46.7%

Return on equity-35.8%+41.3pp

Debt / equity0×0.0×

Current ratio24×-13.6×

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfLongTermDebt.

The official record: Disc Medicine’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Disc Medicine's debt issuance proceeds?: Disc Medicine (IRON) reported debt issuance proceeds of $0 in Q4 2025.
How has Disc Medicine's debt issuance proceeds changed year-over-year?: Disc Medicine's debt issuance proceeds decreased by 100.0% year-over-year, from $7.25M to $0.
What does debt issuance proceeds mean?: Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.